4//SEC Filing
Lawson Jeffrey Harold 4
Accession 0001104659-21-110526
CIK 0001818382other
Filed
Aug 26, 8:00 PM ET
Accepted
Aug 27, 4:10 PM ET
Size
16.9 KB
Accession
0001104659-21-110526
Insider Transaction Report
Form 4
Humacyte, Inc.HUMA
Lawson Jeffrey Harold
DirectorChief Surgical Officer
Transactions
- Award
Common Stock
2021-08-26+7,877→ 7,877 total - Award
Stock Options (right to buy)
2021-08-26+65,649→ 65,649 totalExercise: $3.44Exp: 2026-12-15→ Common Stock (65,649 underlying) - Award
Stock Options (right to buy)
2021-08-26+1,575→ 1,575 totalExercise: $10.28From: 2021-12-14Exp: 2030-12-14→ Common Stock (1,575 underlying) - Award
Stock Options (right to buy)
2021-08-26+118,168→ 118,168 totalExercise: $6.54Exp: 2028-04-12→ Common Stock (118,168 underlying) - Award
Stock Options (right to buy)
2021-08-26+1,194,815→ 1,194,815 totalExercise: $8.48Exp: 2028-06-28→ Common Stock (1,194,815 underlying) - Award
Stock Options (right to buy)
2021-08-26+90,595→ 90,595 totalExercise: $2.56Exp: 2025-12-11→ Common Stock (90,595 underlying)
Footnotes (4)
- [F1]On August 26, 2021, Alpha Healthcare Acquisition Corp. ("AHAC") consummated a business combination (the "Business Combination") by and among AHAC, Hunter Merger Sub, Inc., a Delaware corporation ("Hunter Merger Sub") and Humacyte, Inc., a Delaware corporation ("Legacy Humacyte"), AHAC changed its name to "Humacyte, Inc." and Hunter Merger Sub merged with and into Legacy Humacyte. As part of the Business Combination, each share of Legacy Humacyte stock was exchanged for 0.2626 shares of common stock of Humacyte, Inc.
- [F2]Options are fully vested and exercisable.
- [F3]As part of the Business Combination, each Legacy Humacyte stock option was exchanged for a stock option to acquire 0.2626 shares of common stock of Humacyte, Inc.
- [F4]Options to purchase 2,625 shares of Common Stock granted on 12/14/2020, which vest as follows: (i) one-fifth on the first anniversary of the vesting commencement date, (ii) two-fifths in equal installments over a period of 24 months commencing on the first anniversary of the vesting commencement date, (iii) one-fifth upon the submission of a Biologics License Application to the FDA and (iv) one-fifth upon FDA approval of one of Humacyte's product candidates. Accordingly, columns 5, 7, and 9 of Table II report the number of securities equal to three-fifths of the 12/14/2020 option grant.
Documents
Issuer
Humacyte, Inc.
CIK 0001818382
Entity typeother
Related Parties
1- filerCIK 0001879530
Filing Metadata
- Form type
- 4
- Filed
- Aug 26, 8:00 PM ET
- Accepted
- Aug 27, 4:10 PM ET
- Size
- 16.9 KB